By evaluating each tumor’s neoantigen ITH score (NEOITHS), we found a consistency between neoantigen diversity and the heterogeneity within the CD8+ tumor-infiltrating lymphocytes (TILs) lineage [15], as well as associations of TCR diversity and NEOITHS with clinical outcomes of cancer patients. The gene discussed is CD8A; the disease is cancer.